CLINICAL PRACTICE GUIDELINE Guidance for the Clinician in Rendering Pediatric Care EXECUTIVE SUMMARY FROM THE AMERICAN ACADEMY OF PEDIATRICS

Similar documents
CLINICAL PRACTICE GUIDELINE Guidance for the Clinician in Rendering Pediatric Care EXECUTIVE SUMMARY FROM THE AMERICAN ACADEMY OF PEDIATRICS

Home Cardiorespiratory Monitoring. Description. Section: Durable Medical Equipment Effective Date: April 15, 2017

Brief Resolved Unexplained Events (Apparent Life Threatening Events)

CLINICAL PRACTICE GUIDELINE Guidance for the Clinician in Rendering Pediatric Care

What s a BRUE? /pr. broo / EDAP Conference September 8, 2016 Josh Siembieda, MD FAAP

Age Limit of Pediatrics

2017 Recommendations for Preventive Pediatric Health Care COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE, BRIGHT FUTURES PERIODICITY SCHEDULE WORKGROUP

BRUE and Apnea at Term, how do they relate?

United Recommended Childhood and Adolescent Immunization Schedule States, 2013

(C) The following criteria must be met for coverage of an apnea monitor:

AMERICAN ACADEMY OF PEDIATRICS

From ALTE to BRUE: Brief Resolved Unexplained Events

Cardiac Dysrhythmias and Sports

SmartMonitor Helpful for Filing

The Relationship Between Pertussis Vaccine and Central Nervous System Sequelae: Continuing Assessment

Recommended Childhood and Adolescent Immunization Schedule United States, 2014

Diarrhea is well known to be a leading cause of. Oral Rehydration Therapy for Diarrhea: An Example of Reverse Transfer of Technology

Relationship between the Clinical Characteristics and Intervention Scores of Infants with Apparent Life-threatening Events

AMERICAN ACADEMY OF PEDIATRICS 993 THE NATURAL HISTORY OF CERTAIN CONGENITAL CARDIOVASCULAR MALFORMATIONS. Alexander S. Nadas, M.D.

an educational research program that incorporates parent advocacy, nursing, neuropsychology, psychiatry, neurology, and basic science expertise.

Cyanosis and Pulmonary Disease in Infancy

Bedside Ultrasound in Pediatric Practice

COMMITTEE ON NUTRITION

infant s gestational age, age at phototherapy initiation, and TSB relative to the treatment threshold at phototherapy termination.

Policy Statement Rabies-Prevention Policy Update: New Reduced-Dose Schedule

This has great potential Apparent Life Threatening Events: Another Lengthy Time-consuming i Evaluation? Erich C. Maul, DO, FAAP Associate Program Dire

Update on Tuberculosis Skin Testing of Children

AMERICAN ACADEMY OF PEDIATRICS

ipad Increasing Nickel Exposure in Children

Gastroesophageal Reflux Disease in Infants and Children

Bronchiolitis Management Before and After the AAP Guidelines

Pulmonary Embolism in the Pediatric Emergency Department. abstract ARTICLE

Airway Clearance Devices

In stable term infants, heart rates as low as 70 beats per minute while sleeping are acceptable. (Benitz, 2015)

Strength Training, Weight and Power Lifting, and Body Building by Children and. Adolescent. 0 Committee on Sports Medicine

Antibiotic Prescription With Asthma Medications: Why Is It So Common?

Cost-effectiveness of Metered-Dose Inhalers for Asthma Exacerbations in the Pediatric Emergency Department

Clinical Performance Guideline Neonatal Resource Services Apnea and Bradycardia

Residency Training in Transition of Youth With Childhood-Onset Chronic Disease Manisha S. Patel and Kitty O'Hare. DOI: /peds.

Complete Summary GUIDELINE TITLE

Prenatal Exposure to Methyldopa Leading to Hypertensive Crisis and Cardiac Failure in a Neonate

W E HAVE recently seen two youngsters whose pnesenting complaints were highly suggestive of spinal cord disease but

Clinical Policy Title: Apnea monitors for infants in-home use

Home Pulse Oximetry for Infants and Children

A Systematic Review of Vision Screening Tests for the Detection of Amblyopia

Molluscum BOTE Sign: A Predictor of Imminent Resolution

Financing of Substance Abuse Treatment for Children and Adolescents

Clinical Policy Title: Apnea monitors for infants in-home use

Pediatric Abusive Head Trauma

Pediatric emergencies (SHOCK & COMA) Dr Mubarak Abdelrahman Assistant Professor Jazan University

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Evaluating dyspnea: A practical approach -- When to consider cardiopulmonary exercise testing.

Progress in the Control of Childhood Obesity

Echocardiography Screening of Siblings of Children With Bicuspid Aortic Valve

Understanding Confounding in Research Kantahyanee W. Murray and Anne Duggan. DOI: /pir

Recommendations. for Care of Adults with Epilepsy. Seeking the best treatment from the right doctor at the right time!

How to Recognize a Suspected Cardiac Defect in the Neonate

Epilepsy (and first seizure) on the acute take. Phil Smith Consultant Neurologist University Hospital of Wales, Cardiff

PEDIATRIC SLEEP GUIDELINES Version 1.0; Effective

In recent years, concern has increased markedly

Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

Guideline Summary NGC-5582

PEDIATRIC RESPIRATORY ILLNESS MADE SIMPLE

AMERICAN ACADEMY OF PEDIATRICS. New Developments in Hyperphenylalaninemia. Committee on Nutrition

Apnea in the Newborn

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

Detailed results from the START study

10. Has your child ever been diagnosed with an unexplained seizure disorder or exercise-induced asthma?

symptomatic children whose urine culture was positive for a known uropathogen.

Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Community-Acquired Pneumonia OBSOLETE 2

The Choosing Wisely Project. Disclosures. Learning Objectives 3/18/2014. Marie Gilbert, PA C, DFAAPA

Case #1. Inter-ictal EEG. Difficult Diagnosis Pediatrics. 15 mos girl with medically refractory infantile spasms 2/13/2010

Young Patient Suffers Cardiac Arrest and Brain Damage After Delayed Referral to Specialist

Recommended Childhood and Adolescent Immunization Schedules United States, 2012 COMMITTEE ON INFECTIOUS DISEASES. DOI: /peds.

Learn the steps to identify pediatric muscle weakness and signs of neuromuscular disease.

Bayfield-Ashland Counties EMS Council Pediatric Protocol PP-001 PREHOSPITAL CARE GUIDELINE

AAP Immunization Initiatives JILL HERNANDEZ, MPH

David Dredge, MD MGH Child Neurology CME Course September 9, 2017

Disclosures. Where We Are Going. My Goals for Giving This Talk. Diagnosis and Management of Dysautonomia in the Pediatric Population

Do Not Cite. For Public Comment Period DRAFT MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY

UTI Update: Have We Been Led Astray? Disclosure. Objectives

Evaluation of Dizziness and Fainting in Children and Adolescents

Intermittent Maple Syrup Urine Disease: Two Case Reports

Spine MRI and Spine CT Test Request Tip Sheet

SCOPE OF PRACTICE PGY-4 PGY-6 (or PGY-5 PGY-7 if Medicine/Pediatrics resident)

Corporate Medical Policy

Lichen sclerosus (LS) is an uncommon inflammatory. Constipation as a Feature of Anogenital Lichen Sclerosus in Children

Policy. ( Number: *Pleasesee amendment forpennsylvaniamedicaidattheend ofthis CPB.

The 14 th International Fragile X Conference, Garden Grove, CA, Friday, July 18 th, 2014

The Role of Adrenal Steroids in the Treatment of Tuberculosis

Fatal Lumbar Puncture: Fact Versus Fiction An Approach to a Clinical Dilemma

NORMAL LABORATORY VALUES FOR CHILDREN

Comparison of Mercury and Aneroid Blood Pressure Measurements in Youth

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Multiple Sleep Latency Testing

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Genetics

Basic Standards for Osteopathic Fellowship Training in Sleep Medicine

Predictive Diagnosis. Clustering to Better Predict Heart Attacks x The Analytics Edge

Transcription:

CLINICAL PRACTICE GUIDELINE Guidance for the Clinician in Rendering Pediatric Care Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower- Risk Infants: Executive Summary Joel S. Tieder, MD, MPH, FAAP, Joshua L. Bonkowsky, MD, PhD, FAAP, Ruth A. Etzel, MD, PhD, FAAP, Wayne H. Franklin, MD, MPH, MMM, FAAP, David A. Gremse, MD, FAAP, Bruce Herman, MD, FAAP, Eliot S. Katz, MD, FAAP, Leonard R. Krilov, MD, FAAP, J. Lawrence Merritt II, MD, FAAP, Chuck Norlin, MD, FAAP, Jack Percelay, MD, MPH, FAAP, Robert E. Sapién, MD, MMM, FAAP, Richard N. Shiffman, MD, MCIS, FAAP, Michael B.H. Smith, MB, FRCPCH, FAAP, SUBCOMMITTEE ON APPARENT LIFE THREATENING EVENTS EXECUTIVE SUMMARY This clinical practice guideline has 2 primary objectives. First, it recommends the replacement of the term apparent life-threatening event (ALTE) with a new term, brief resolved unexplained event (BRUE). Second, it provides an approach to evaluation and management that is based on the risk that the infant will have a repeat event or has a serious underlying disorder. Clinicians should use the term BRUE to describe an event occurring in an infant younger than 1 year when the observer reports a sudden, brief, and now resolved episode of 1 of the following: (1) cyanosis or pallor; (2) absent, decreased, or irregular breathing; (3) marked change in tone (hyper- or hypotonia); and (4) altered level of responsiveness. Moreover, clinicians should diagnose a BRUE only when there is no explanation for a qualifying event after conducting an appropriate history and physical examination (see Tables 2 and 3 in www. pediatrics. org/ cgi/ doi/ 10. 1542/ peds. 2016-0591). Among infants who present for medical attention after a BRUE, the guideline identifies (1) lower-risk patients on the basis of history and physical examination, for whom evidencebased guidelines for evaluation and management are offered, and (2) higher-risk patients, whose history and physical examination suggest the need for further investigation, monitoring, and/or treatment, but for whom recommendations are not offered (because of insufficient evidence or the availability of guidance from other clinical practice guidelines specific to their presentation or diagnosis). Recommendations in this guideline apply only to lower-risk patients, This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication. The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate. All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time. DOI: 10.1542/peds.2016-0591 PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright 2016 by the American Academy of Pediatrics To cite: Tieder JS, Bonkowsky JL, Etzel RA, et al. Brief Resolved Unexplained Events (Formerly Apparent Life- Threatening Events) and Evaluation of Lower-Risk Infants: Executive Summary. Pediatrics. 2016;137(5):e20160591 PEDIATRICS Volume 137, number 5, May 2016 :e 20160591 FROM THE AMERICAN ACADEMY OF PEDIATRICS

who are defined by (1) age >60 days; (2) gestational age 32 weeks and postconceptional age 45 weeks; (3) occurrence of only 1 BRUE (no prior BRUE ever and not occurring in clusters); (4) duration of BRUE <1 minute; (5) no cardiopulmonary resuscitation by trained medical provider required; (6) no concerning historical features; and (7) no concerning physical examination findings (Fig 1). This clinical practice guideline also provides implementation support and suggests directions for future research. The term ALTE originated from a 1986 National Institutes of Health Consensus Conference on Infantile Apnea and was intended to replace the term near-miss sudden infant death syndrome (SIDS). 1 An ALTE was defined as [a]n episode that is frightening to the observer and that is characterized by some combination of apnea (central or occasionally obstructive), color change (usually cyanotic or pallid but occasionally erythematous or plethoric), marked change in muscle tone (usually marked limpness), choking, or gagging. In some cases, the observer fears that the infant has died. 2 Although the definition of ALTE enabled researchers to establish over time that these events were a separate entity from SIDS, the clinical application of this classification, which describes a constellation of observed, subjective, and nonspecific symptoms, has raised significant challenges for clinicians and parents in the evaluation and care of these infants. 3 Although a broad range of disorders can present as an ALTE (eg, child abuse, congenital abnormalities, epilepsy, inborn errors of metabolism, and infections), for a majority of well-appearing infants, the risk of a recurrent event or a serious underlying disorder is extremely low. ALTEs can create a feeling of uncertainty in both the caregiver and the clinician. Clinicians may feel compelled to perform tests and hospitalize the patient even though this may subject the patient to unnecessary risk and is unlikely to lead to a treatable diagnosis or prevent future events. 2,4,5 Understanding the risk of an adverse outcome for an infant who has experienced an ALTE has been difficult because of the nonspecific nature and variable application of the ALTE definition in research. A recent systematic review of nearly 1400 ALTE publications spanning 4 decades concluded that risk of a subsequent or underlying disorder could not be quantified because of the variability in case definitions across studies. 3 Although there are history and physical examination factors that can determine lower or higher risk, it is clear that the term ALTE must be replaced to advance the quality of care and improve research. This guideline is intended for use primarily by clinicians providing care for infants who have experienced a BRUE, as well as their families. The guideline may be of interest to payers, but it is not intended to be used for reimbursement or to determine insurance coverage. This guideline is not intended as the sole source of guidance in the evaluation and management of BRUEs and specifically does not address higher-risk BRUE patients. Rather, it is intended to assist clinicians by providing a framework for clinical decision making. It is not intended to replace clinical judgment, and these recommendations may not provide the only appropriate approach to the management of this problem. This guideline is intended to provide a patient- and family-centered approach to care, reduce unnecessary and costly medical interventions, and improve patient outcomes. It includes recommendations for diagnosis, risk-based stratification, monitoring, disposition planning, effective communication with the patient and family, guideline implementation and evaluation, and future research. In addition, it aims to help clinicians determine the presence of a serious underlying cause and a safe disposition by alerting them to the most significant features of the clinical history and physical examination on which to base an approach for diagnostic testing and hospitalization. Key action statements are summarized in Table 1. SUBCOMMITTEE ON BRIEF RESOLVED UNEXPLAINED EVENTS (FORMERLY REFERRED TO AS APPARENT LIFE THREATENING EVENTS); OVERSIGHT BY THE COUNCIL ON QUALITY IMPROVEMENT AND PATIENT SAFETY Joel S. Tieder, MD, MPH, FAAP, Chair Joshua L. Bonkowsky, MD, PhD, FAAP, Pediatric Neurologist Ruth A. Etzel, MD, PhD, FAAP, Pediatric Epidemiologist Wayne H. Franklin, MD, MPH, MMM, FAAP, Pediatric Cardiologist David A. Gremse, MD, FAAP, Pediatric Gastroenterologist Bruce Herman, MD, FAAP, Child Abuse and Neglect Eliot Katz, MD, FAAP, Pediatric Pulmonologist Leonard R. Krilov, MD, FAAP, Pediatric Infectious Diseases J. Lawrence Merritt, II, MD, FAAP, Clinical Genetics and Biochemical Genetics Chuck Norlin, MD, FAAP, Pediatrician Robert E. Sapién, MD, MMM, FAAP, Pediatric Emergency Medicine Richard Shiffman, MD, FAAP, Partnership for Policy Implementation Representative Michael B.H. Smith, MB, FRCPCH, FAAP, Hospital Medicine e2 FROM THE AMERICAN ACADEMY OF PEDIATRICS

FIGURE 1 Diagnosis, risk classification, and recommended management of a BRUE. *Refer to Tables 3 and 4 in www. pediatrics. org/ cgi/ doi/10.1542/peds.2016-0591 for the determination of an appropriate and negative history and PE. **Refer to Figure 2 in www. pediatrics. org/ cgi/ doi/ 10.1542/peds.2016-0591 for the American Academy of Pediatrics method for rating of evidence and recommendations. CPR, cardiopulmonary resuscitation; CSF, cerebrospinal fluid; ECG, electrocardiogram; FH, family history; GER, gastroesophageal reflux; PE, physical examination; WBC, white blood cell. PEDIATRICS Volume 137, number 5, May 2016 e3

TABLE 1 Summary of Key Action Statements for Lower-Risk BRUEs When managing an infant who is >60 d and <1 y of age and who, on the basis of a thorough history and physical examination, meets criteria for having experienced a lower-risk BRUE, clinicians: 1. Cardiopulmonary Evaluation 1A. Need not admit infants to the hospital solely for cardiorespiratory monitoring. B; Weak 1B. May briefly monitor patients with continuous pulse oximetry and serial observations. D; Weak 1C. Should not obtain chest radiograph. B; Moderate 1D. Should not obtain a measurement of venous or arterial blood gas. B; Moderate 1E. Should not obtain an overnight polysomnograph. B; Moderate 1F. May obtain a 12-lead electrocardiogram. C; Weak 1G. Should not obtain an echocardiogram. C; Moderate 1H. Should not initiate home cardiorespiratory monitoring. B; Moderate 2. Child Abuse Evaluation 2A. Need not obtain neuroimaging (CT, MRI, or ultrasonography) to detect child abuse. C; Weak 2B. Should obtain an assessment of social risk factors to detect child abuse. C; Moderate 3. Neurologic Evaluation 3A. Should not obtain neuroimaging (CT, MRI, or ultrasonography) to detect neurologic disorders. C; Moderate 3B. Should not obtain an EEG to detect neurologic disorders. C; Moderate 3C. Should not prescribe antiepileptic medications for potential neurologic disorders. C; Moderate 4. Infectious Disease Evaluation 4A. Should not obtain a WBC count, blood culture, or cerebrospinal fluid analysis or culture to detect an occult B; Strong bacterial infection. 4B. Need not obtain a urinalysis (bag or catheter). C; Weak 4C. Should not obtain chest radiograph to assess for pulmonary infection. B; Moderate 4D. Need not obtain respiratory viral testing if rapid testing is available. C; Weak 4E. May obtain testing for pertussis. B; Weak 5. Gastrointestinal Evaluation 5A. Should not obtain investigations for GER (eg, upper gastrointestinal tract series, ph probe, endoscopy, barium C; Moderate contrast study, nuclear scintigraphy, and ultrasonography). 5B. Should not prescribe acid suppression therapy. C; Moderate 6. Inborn Error of Metabolism Evaluation 6A. Need not obtain measurement of serum lactic acid or serum bicarbonate. C; Weak 6B. Should not obtain a measurement of serum sodium, potassium, chloride, blood urea nitrogen, creatinine, C; Moderate calcium, or ammonia. 6C. Should not obtain a measurement of venous or arterial blood gases. C; Moderate 6D. Need not obtain a measurement of blood glucose. C; Weak 6E. Should not obtain measurements of urine organic acids, plasma amino acids, or plasma acylcarnitines. C; Moderate 7. Anemia Evaluation 7A. Should not obtain laboratory evaluation for anemia. C; Moderate 8. Patient- and Family-Centered Care 8A. Should offer resources for CPR training to caregiver. C; Moderate 8B. Should educate caregivers about BRUEs. C; Moderate 8C. Should use shared decision making. C; Moderate CPR, cardiopulmonary resuscitation; CT, computed tomography; GER, gastroesophageal reflux; WBC, white blood cell. Evidence Quality; Strength of Recommendation Jack Percelay, MD, MPH, FAAP, Liaison, Society for Hospital Medicine STAFF Kymika Okechukwu, MPA ABBREVIATIONS ALTE: apparent life-threatening event BRUE: brief resolved unexplained event SIDS: sudden infant death syndrome REFERENCES 1. National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring, Sept 29 to Oct 1, 1986. Pediatrics. 1987;79(2). Available at: www. pediatrics. org/ cgi/ content/ full/ 79/ 2/ e292 2. McGovern MC, Smith MB. Causes of apparent life threatening events in infants: a systematic review. Arch Dis Child. 2004;89(11):1043 1048 3. Tieder JS, Altman RL, Bonkowsky JL, et al Management of apparent life-threatening events in infants: a systematic review. J Pediatr. 2013;163(1):94 99, e91 e96 4. Brand DA, Altman RL, Purtill K, Edwards KS. Yield of diagnostic testing in infants who have had an apparent life-threatening event. Pediatrics. 2005;115(4). Available at: www. pediatrics. org/cgi/content/full/115/4/e885 5. Green M. Vulnerable child syndrome and its variants. Pediatr Rev. 1986; 8(3):75 80 e4 FROM THE AMERICAN ACADEMY OF PEDIATRICS

Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants: Executive Summary Joel S. Tieder, Joshua L. Bonkowsky, Ruth A. Etzel, Wayne H. Franklin, David A. Gremse, Bruce Herman, Eliot S. Katz, Leonard R. Krilov, J. Lawrence Merritt II, Chuck Norlin, Jack Percelay, Robert E. Sapién, Richard N. Shiffman, Michael B.H. Smith and SUBCOMMITTEE ON APPARENT LIFE THREATENING EVENTS Pediatrics 2016;137;; originally published online April 25, 2016; DOI: 10.1542/peds.2016-0591 Updated Information & Services References Subspecialty Collections Permissions & Licensing Reprints including high resolution figures, can be found at: /content/137/5/e20160591.full.html This article cites 4 articles, 2 of which can be accessed free at: /content/137/5/e20160591.full.html#ref-list-1 This article, along with others on similar topics, appears in the following collection(s): Fetus/Newborn Infant /cgi/collection/fetus:newborn_infant_sub Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: /site/misc/permissions.xhtml Information about ordering reprints can be found online: /site/misc/reprints.xhtml PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants: Executive Summary Joel S. Tieder, Joshua L. Bonkowsky, Ruth A. Etzel, Wayne H. Franklin, David A. Gremse, Bruce Herman, Eliot S. Katz, Leonard R. Krilov, J. Lawrence Merritt II, Chuck Norlin, Jack Percelay, Robert E. Sapién, Richard N. Shiffman, Michael B.H. Smith and SUBCOMMITTEE ON APPARENT LIFE THREATENING EVENTS Pediatrics 2016;137;; originally published online April 25, 2016; DOI: 10.1542/peds.2016-0591 The online version of this article, along with updated information and services, is located on the World Wide Web at: /content/137/5/e20160591.full.html PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.